The growth in the historic period can be attributed to increasing infertility rates, success of ivf technologies, delayed parenthood trends, availability of assisted reproduction clinics, established hormonal stimulation regimens.
The growth in the forecast period can be attributed to growth in fertility tourism, rising acceptance of assisted reproduction, technological advances in ivf, expansion of fertility clinics in emerging markets, improved treatment success rates. Major trends in the forecast period include rising use of hormonal stimulation in ivf, growth in assisted reproductive procedures, increased demand for purified fsh therapies, expansion of fertility treatment centers, improved ovarian stimulation protocols.
The increasing infertility rates are anticipated to drive the growth of the Bravelle market in the coming years. Infertility refers to the inability to conceive after a year or more of regular unprotected intercourse or to carry a pregnancy to term. The rise in infertility rates is largely due to delayed childbearing, as fertility naturally declines with age, reducing the likelihood of conception. Bravelle addresses infertility by stimulating the ovaries to produce multiple eggs, enhancing the chances of successful fertilization and pregnancy, particularly in women with ovulatory disorders or those undergoing assisted reproductive techniques such as IVF. For example, in May 2025, the Office for National Statistics (ONS), a UK-based government department, reported that the total fertility rate (TFR) in England and Wales declined from 1.44 children per woman in 2023 to 1.41 in 2024, a 2.1% decrease, reflecting a rise in infertility rates. Thus, increasing infertility rates are driving the growth of the Bravelle market.
The growing demand for personalized medicine is expected to further propel the market. Personalized medicine involves tailoring medical treatment to individual characteristics, such as genetics, lifestyle, and environment, to improve treatment effectiveness. The increasing demand is driven by advancements in genomics, a focus on precision healthcare, and rising awareness of the benefits of individualized treatments. Bravelle, a recombinant form of follicle-stimulating hormone (FSH), enables personalized treatment by stimulating ovarian follicle growth in women undergoing fertility therapy, allowing protocols to be customized according to individual responses for optimal egg production and higher chances of pregnancy. For instance, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that the FDA approved 16 new personalized treatments for rare disease patients in 2023, up from 6 in 2022, including seven cancer drugs and three for other conditions. Therefore, the growing demand for personalized medicine is driving the growth of the Bravelle market.
In April 2023, Ferring International Center S.A., a Switzerland-based biopharmaceutical company specializing in Bravelle, partnered with BII Holdings A/S. The collaboration aims to accelerate innovation in women’s health by supporting early-stage start-ups and projects in reproductive medicine, addressing the underinvestment in female-specific healthcare conditions. BII Holdings A/S, based in Denmark, is a biotechnology startup providing innovative solutions and services in life sciences and biotechnology.
Major companies operating in the bravelle market are Ferring Pharmaceuticals.
North America was the largest region in the bravelle market in 2025. The regions covered in the bravelle market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the bravelle market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Tariffs have influenced the bravelle market by increasing costs of imported biologic raw materials, purification equipment, and sterile manufacturing supplies. These impacts are more pronounced in regions dependent on cross border pharmaceutical inputs such as asia pacific. Fertility clinics have experienced higher treatment costs due to product pricing pressures. However, tariffs have encouraged regional manufacturing investments. This supports more stable supply of fertility hormones over time.
The bravelle market research report is one of a series of new reports that provides bravelle market statistics, including bravelle industry global market size, regional shares, competitors with a bravelle market share, detailed bravelle market segments, market trends and opportunities, and any further data you may need to thrive in the bravelle industry. This bravelle market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Bravelle is a highly purified human follicle-stimulating hormone (FSH) used in fertility treatments, particularly for women undergoing in vitro fertilization (IVF). It stimulates the ovaries to produce multiple eggs, which is essential for successful IVF, and is often prescribed to women who have difficulty producing eggs naturally. Bravelle is commonly used alongside other fertility medications to improve the chances of pregnancy.
The primary segments of the bravelle market include fresh IVF cycles, thawed IVF cycles, and donor egg IVF cycles. A fresh IVF cycle involves retrieving eggs from a woman’s ovaries, fertilizing them in the lab with sperm, and transferring the resulting embryos into the uterus. Techniques associated with Bravelle use include in vitro fertilization (IVF), artificial insemination (AI-IUI), frozen embryo transfer (FET), and other methods. Its applications cover human reproduction, research, and reproductive toxicology, with end users including fertility clinics, hospitals, surgical centers, and clinical research institutes.
The bravelle market consists of sales of bravelle 75 iu injection, bravelle 100 iu injection, and bravelle urofollitropin. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The growth in the forecast period can be attributed to growth in fertility tourism, rising acceptance of assisted reproduction, technological advances in ivf, expansion of fertility clinics in emerging markets, improved treatment success rates. Major trends in the forecast period include rising use of hormonal stimulation in ivf, growth in assisted reproductive procedures, increased demand for purified fsh therapies, expansion of fertility treatment centers, improved ovarian stimulation protocols.
The increasing infertility rates are anticipated to drive the growth of the Bravelle market in the coming years. Infertility refers to the inability to conceive after a year or more of regular unprotected intercourse or to carry a pregnancy to term. The rise in infertility rates is largely due to delayed childbearing, as fertility naturally declines with age, reducing the likelihood of conception. Bravelle addresses infertility by stimulating the ovaries to produce multiple eggs, enhancing the chances of successful fertilization and pregnancy, particularly in women with ovulatory disorders or those undergoing assisted reproductive techniques such as IVF. For example, in May 2025, the Office for National Statistics (ONS), a UK-based government department, reported that the total fertility rate (TFR) in England and Wales declined from 1.44 children per woman in 2023 to 1.41 in 2024, a 2.1% decrease, reflecting a rise in infertility rates. Thus, increasing infertility rates are driving the growth of the Bravelle market.
The growing demand for personalized medicine is expected to further propel the market. Personalized medicine involves tailoring medical treatment to individual characteristics, such as genetics, lifestyle, and environment, to improve treatment effectiveness. The increasing demand is driven by advancements in genomics, a focus on precision healthcare, and rising awareness of the benefits of individualized treatments. Bravelle, a recombinant form of follicle-stimulating hormone (FSH), enables personalized treatment by stimulating ovarian follicle growth in women undergoing fertility therapy, allowing protocols to be customized according to individual responses for optimal egg production and higher chances of pregnancy. For instance, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that the FDA approved 16 new personalized treatments for rare disease patients in 2023, up from 6 in 2022, including seven cancer drugs and three for other conditions. Therefore, the growing demand for personalized medicine is driving the growth of the Bravelle market.
In April 2023, Ferring International Center S.A., a Switzerland-based biopharmaceutical company specializing in Bravelle, partnered with BII Holdings A/S. The collaboration aims to accelerate innovation in women’s health by supporting early-stage start-ups and projects in reproductive medicine, addressing the underinvestment in female-specific healthcare conditions. BII Holdings A/S, based in Denmark, is a biotechnology startup providing innovative solutions and services in life sciences and biotechnology.
Major companies operating in the bravelle market are Ferring Pharmaceuticals.
North America was the largest region in the bravelle market in 2025. The regions covered in the bravelle market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the bravelle market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Tariffs have influenced the bravelle market by increasing costs of imported biologic raw materials, purification equipment, and sterile manufacturing supplies. These impacts are more pronounced in regions dependent on cross border pharmaceutical inputs such as asia pacific. Fertility clinics have experienced higher treatment costs due to product pricing pressures. However, tariffs have encouraged regional manufacturing investments. This supports more stable supply of fertility hormones over time.
The bravelle market research report is one of a series of new reports that provides bravelle market statistics, including bravelle industry global market size, regional shares, competitors with a bravelle market share, detailed bravelle market segments, market trends and opportunities, and any further data you may need to thrive in the bravelle industry. This bravelle market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Bravelle is a highly purified human follicle-stimulating hormone (FSH) used in fertility treatments, particularly for women undergoing in vitro fertilization (IVF). It stimulates the ovaries to produce multiple eggs, which is essential for successful IVF, and is often prescribed to women who have difficulty producing eggs naturally. Bravelle is commonly used alongside other fertility medications to improve the chances of pregnancy.
The primary segments of the bravelle market include fresh IVF cycles, thawed IVF cycles, and donor egg IVF cycles. A fresh IVF cycle involves retrieving eggs from a woman’s ovaries, fertilizing them in the lab with sperm, and transferring the resulting embryos into the uterus. Techniques associated with Bravelle use include in vitro fertilization (IVF), artificial insemination (AI-IUI), frozen embryo transfer (FET), and other methods. Its applications cover human reproduction, research, and reproductive toxicology, with end users including fertility clinics, hospitals, surgical centers, and clinical research institutes.
The bravelle market consists of sales of bravelle 75 iu injection, bravelle 100 iu injection, and bravelle urofollitropin. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Bravelle Market Characteristics
3. Bravelle Market Supply Chain Analysis
4. Global Bravelle Market Trends and Strategies
5. Bravelle Market Analysis of End Use Industries
7. Global Bravelle Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Bravelle Total Addressable Market (TAM) Analysis for the Market
9. Bravelle Market Segmentation
10. Bravelle Market Regional and Country Analysis
11. Asia-Pacific Bravelle Market
12. China Bravelle Market
13. India Bravelle Market
14. Japan Bravelle Market
15. Australia Bravelle Market
16. South Korea Bravelle Market
17. Western Europe Bravelle Market
18. UK Bravelle Market
19. Germany Bravelle Market
20. France Bravelle Market
21. Eastern Europe Bravelle Market
22. North America Bravelle Market
23. USA Bravelle Market
24. Canada Bravelle Market
25. South America Bravelle Market
26. Middle East Bravelle Market
27. Africa Bravelle Market
29. Bravelle Market Competitive Landscape and Company Profiles
32. Bravelle Market High Potential Countries, Segments and Strategies
33. Appendix
Executive Summary
Bravelle Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses bravelle market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for bravelle? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The bravelle market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Type: Fresh In vitro fertilization (IVF) Cycle; Thawed In vitro fertilization (IVF) Cycle; Donor Egg In vitro fertilization (IVF) Cycle2) By Technique: In Vitro Fertilization (IVF); Artificial Insemination (AI-IUI); Frozen Embryo Transfer (FET); Other Techniques
3) By Application: Human Reproduction; Research And Reproductive Toxicology
4) By End User: Fertility Clinics; Hospitals; Surgical Centers; Clinical Research Institutes
Companies Mentioned: Ferring Pharmaceuticals
Countries: Australia; India; China; South Korea; Japan; UK; France; Germany; USA; Canada.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Bravelle market report include:- Ferring Pharmaceuticals
